TITLE: Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including MERTK, TEK, FGFR2, and FGFR1: a molecular and clinicopathologic analysis

Yajuan J. Liu1*, Wenjing Wang1, Jeffrey Yeh2, Yu Wu1, Jose G. Mantilla1, Christopher D.M. Fletcher3, Robert W. Ricciotti1, Eleanor Y. Chen1*

1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States

2Department of Biology, University of Washington, Seattle, Washington, United States

3Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States.

*Correspondence:
Eleanor Y. Chen, MD, PhD
Associate Professor
Department of Pathology
University of Washington School of Medicine
1959 NE Pacific St, Seattle, WA 98195
Box 357470
Email: eleanor2@uw.edu

Yajuan Liu, PhD
Associate Professor
Department of Laboratory Medicine and Pathology
University of Washington School of Medicine
1959 NE Pacific St, Seattle, WA 98195
Box 357470
Email: yajuan@uw.edu

Running title: Chondroid mesenchymal tumor with FN1 fusion
ABSTRACT

Translocations involving *FN1* have been described in a variety of neoplasms, which share the presence of cartilage matrix and a variable extent of calcification. Fusions of *FN1* to *FGFR1* or *FGFR2* have been reported in nine soft tissue chondromas, mostly demonstrated indirectly by FISH analysis. Delineation of *FN1* fusions with various partner genes will facilitate our understanding of the pathogenesis and diagnostic classification of these neoplasms. In this study, we present molecular, clinical and pathologic features of 9 cartilaginous soft tissue neoplasms showing a predilection for the TMJ region and the extremities. We analyzed for gene fusions with precise breakpoints using targeted RNA-seq with a 115-gene panel, including *FN1*, *FGFR1* and *FGFR2*. All 9 cases were positive for a gene fusion, including two novel fusions, *FN1-MERTK* and *FN1-TEK*, each in one case, recurrent *FN1-FGFR2* in 5 cases, *FN1-FGFR1* without the Ig3 domain in one case, and *FGFR1-PLAG1* in one case. The breakpoints in the 5’ partner gene *FN1* ranged from exons 11-48, retaining the domains of signal peptide, FN1, FN2, and/or FN3, while the 3’ partner genes retained the trans-membrane domain, tyrosine kinase domains and/or Ig domain. The tumors with *FN1-FGFR1*, *FN1-FGFR2* and *FN1-MERTK* fusions are generally characterized by nodular/lobular growth of polygonal to stellate cells within a chondroid matrix, often accompanied by various patterns of calcification. These features resemble those as described for the chondroblastoma-like variant of soft tissue chondroma. Additional histologic findings include calcium pyrophosphate dehydrate deposition and features resembling tenosynovial giant cell tumor. Overall, while the tumors from our series show significant morphologic overlap with chondroblastoma-like soft tissue chondroma, we describe novel findings that expand the morphologic spectrum of these neoplasms and have therefore
labeled them as “calcified chondroid mesenchymal neoplasms.” These neoplasms represent a distinct pathologic entity given the presence of recurrent \textit{FN1}-receptor tyrosine kinase fusions.
INTRODUCTION:

Translocation events involving *FN1* have been described in a wide variety of neoplasms, all of which share the presence of cartilage matrix and a variable extent of calcification (1–3). Specifically, synovial chondromatosis, characterized by multinodular growth of mature cartilaginous tissue with clustering of chondrocytes has recently been shown as frequently harboring the *FN1-ACVR2* translocation (2). Fusion of *FN1* to *FGFR1* or *FGFR2* has also been described in soft tissue chondroma, particularly in examples showing grungy to lacy (chondroblastoma-like) calcification (2). Phosphaturic mesenchymal tumor, frequently harboring *FN1-FGFR1* or *FN1-EGF* fusions, shows variable histologic features, and is generally characterized as a proliferation of bland spindled to stellate cells with associated flocculent-appearing calcified, chondroid or ossified matrix within a highly vascularized stroma (3,4). Lastly, calcifying aponeurotic fibroma, a proliferation of bland fibroblastic cells with calcified fibrocartilage-like nodules, has been shown to harbor recurrent *FN1-EGF* gene fusions (1). Besides these four entities, these histologic features may be seen in a wide spectrum of cartilaginous neoplasms of soft tissue. These include so-called chondroid tenosynovial giant cell tumor (TGCT), calcium pyrophosphate dihydrate (CPPD) deposition disease (tophaceous pseudogout), and chondroblastoma (5–9). These tumors in some cases share overlap in cytomorphology and histologic features, sometimes making precise histologic classification challenging.

In this study, we present the molecular, clinical and pathologic features of 9 cases of soft tissue chondroid tumors with calcification, the majority of which show an anatomic predilection for the temporo-mandibular joint (TMJ). We also review the literature and discuss differential
diagnosis of various entities highlighting their overlapping and distinct histologic and molecular features.

METHODS AND MATERIALS:

Case selection and clinicopathological characterization

This project was approved by the Institutional Review Board at the University of Washington. Six cases from the series in this study were retrieved from the archives of the Department of Pathology at the University of Washington, and 3 cases were retrieved from the archived cases in consultation to C.D.F. at the Brigham and Women’s Hospital. The H&E slides were independently reviewed by 4 pathologists, E.C., R.R., J.M. and C.D.M.F.

Targeted RNA sequencing

All nine specimens used in this study were archived formalin-fixed paraffin embedded (FFPE) tissue specimens. Total nucleic acid (TNA) was extracted from the FFPE specimens using AllPrep DNA/RNA FFPE kit according to the manufacturer's recommended protocol (Qiagen, Valencia, CA, USA). The Fusionplex RNA-sequencing assay was performed using a customized 115-gene panel covering a wide spectrum of cancer genes known for their involvement in gene fusions in neoplasia including, but not limited to, FN1, CSF1, FGFR1, and FGFR2 (ArcherDx, Inc. Boulder, CO). The methods for Fusionplex RNA-sequencing analysis have been described previously (10).

RT-PCR and Sanger sequencing confirmation
For the positive fusions detected by targeted RNA-seq, RT-PCR and Sanger sequencing was performed to confirm the fusions and breakpoints at RNA level. cDNAs were synthesized by random priming with Fusionplex reagent kit (ArcherDX, Boulder, CO, USA), then were subjected to polymerase chain reaction (PCR) using FastStart Taq Polymerase (Roche Diagnostics, Indianapolis, IN, USA) with specific primers designed for each partner gene (Table S1). PCR products were cloned using TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA) and then were Sanger-sequenced using Eurofins Genomics Tube Sequencing service (Eurofins Genomics, Louisville, KY, USA).

RESULTS:

Clinical and Pathologic Findings:

Our series of 9 patients includes 4 women and 5 men with a mean age of 56.5 years (range 36 to 72 years). Anatomic locations include the temporomandibular joint and/or temporal bone in 5 cases (56%), hand/digits in 3 cases (33%), and foot in 1 case (11%). Tumor size, when available, ranged from 0.5 to 4.0 cm (mean 3.1 cm). All tumors were removed by surgical excision. Follow-up information was available for 2 cases, with a duration of 1 year each. No recurrence or metastasis was reported in any case. See Table 1 for complete clinicopathologic information.

Histologically, all tumors showed multinodular architecture and chondroid to cartilaginous matrix (Fig. 1 A-B, cases 2 and 4) with increased cellularity towards the periphery of the nodules. The matrix frequently showed calcification that was coarse or grungy to lacy (chondroblastoma-like) (Fig. 1 C-D, cases 2 and 4). Remarkably, the grungy calcifications in case 5 were intensely basophilic, appeared crystalline (Fig. 2 A-B), and examination using polarized light revealed refractive rhomboid crystals consistent with calcium pyrophosphate...
dihydrate (CPPD) deposition (Fig. 2 C). The tumor cells within the chondroid/cartilage matrix were polygonal to stellate with abundant eosinophilic cytoplasm and eccentrically placed nuclei with small nucleoli, while the cells in fibrous septa were more often smaller and spindled with fibroblastic features (Fig. 3 A-C, cases 2, 3 and 8). While osteoclast-like giant cells were present in all cases and careful examination could often find at least focal areas resembling tenosynovial giant cell tumor (epithelioid to histiocytoid cells with eccentric nuclei and hemosiderin deposition), TGCT-like features were particularly prominent in case 9 (Fig. 4 A-B) which also had the least amount of chondroid stroma. For comparison, we tested a case in our archives previously classified as TGCT with focal chondroid metaplasia occurring in the TMJ (Figure 4 C-D), and that tumor was negative for gene fusions, including FN1, FGFR1, FGFR2 and CSF1, using our targeted gene panel.

**Molecular Findings:**

By targeted RNA sequencing, an in-frame gene fusion was detected in all 9 cases. In 8 tumors, the fusion genes were comprised of FN1 as the 5’ partner gene and various 3’ partner genes including FGFR2 in 5 cases (cases 1-5), FGFR1 in one case (case 7) and novel partner genes MERTK and TEK in two cases (cases 8 and 9, respectively) (Table 1, Figure 2). An FGFR1-PLAG1 fusion gene was detected in 1 tumor with FGFR1 as the 5’ partner and PLAG1 as the 3’ partner (case 6). All fusion transcripts were further verified by RT-PCR and Sanger sequencing (Figure S1).

Gene fusions involved various breakpoints within the coding sequencing of the 5’ partner gene FN1, ranging from the 3’ end of exon 11 to exon 48, retaining signal peptide domain (SP), all FN type 1 domains (FN1 binding assembly domain) and FN type 2 domains, and up to sixteen
FN type 3 domains (Figure 5). The various 3’t partner genes of the fusion transcripts had breakpoints at the 5’ ends of exon 5 to exon 7 of FRGR2 in 5 cases, exon 9 of FGFR1, exon 2 of MERTK, and exon 13 of TEK (Figure 5, Table 1), retaining trans-membrane domain (TM) and tyrosine kinase domain (TK) in all eight cases. However, up to two extracellular FGF-binding (Ig-like) domains were retained in the fusions, including two of three Ig-like domains (Ig2 and Ig3) of FGFR2 in cases 2-5, Ig3 only of FGFR2 in case 1, and Ig1 and Ig2 of MERTK in case 8, no Ig-like domain of FGFR1 in case 7, and no Ig-like domain of TEK in case 9 (Figure 5, Table 1). Of note, two alternatively spliced fusion transcripts were detected in case 2. One tumor harbored an FGFR1-PLAG1 fusion gene with breakpoints between exons 1 and 2 of FGFR1 and between exons 2 and 3 of PLAG1.

DISCUSSION:

In this study we characterize the presence of FN1 fusion with genes encoding receptor tyrosine kinases in 8 calcified chondroid mesenchymal neoplasms as well as FGFR1-PLAG1 in one tumor (Table 1). Gene fusions involving FN1-FGFR2 or FN1-FGFR1 have been recently described in a subset of soft tissue chondromas, which were mostly demonstrated indirectly using break-apart FISH probes for FN1, FGFR1, and/or FGFR2 (2). To our knowledge, only one case of soft tissue chondroma with FN1-FGFR2 has been characterized by RNA sequencing and showed a fusion between exons 1-19 of FN1 and exons 7-17 of FGFR2 (2). The breakpoints in FN1 and FGFR2 reported in this case are in the range of breakpoints defined in the five tumors harboring FN1-FGFR2 fusions in our series (Figure 5B). We also describe two novel gene fusions, FN1-MERTK and FN1-TEK (Table 1, Figure 5). FN1 encodes fibronectin-1, a glycoprotein present in a dimeric form in plasma and in dimeric/multimeric forms at the cell
surface and in extracellular matrix, which participates in cell adhesion and migration processes (11). All fusion partners of \( FN1 \) detected in our series encode for receptor tyrosine kinases; these include \( FGFR2 \) (fibroblast growth factor receptor 2), \( FGFR1 \) and \( MERTK \) (MER proto-oncogene, tyrosine kinase). These fusions result in the in-frame fusion of the N-terminal region of FN1 to the intact transmembrane and tyrosine kinase domains of the receptor tyrosine kinase, and as a result, may promote dimerization of the fused receptor through the fibronectin domain and thereby lead to aberrant signal activation as previously hypothesized (3). The presence of fusions involving these potentially targetable receptor tyrosine kinases suggests potential alternative therapeutic avenues for treating such tumors if needed.

Fusions of \( FN1 \) to other receptor tyrosine kinases have also been detected in a variety of neoplasms other than soft tissue chondroma, including \( FN1-FGFR1 \) and \( FN1-FGF1 \) in phosphaturic mesenchymal tumor (3,12), \( FN1-EGF \) in lipofibromatosis and calcifying aponeurotic fibroma (1,13), \( FN1-AVCR2A \) in synovial chondromatosis (2), \( FN1-ALK \) in gastrointestinal leiomyoma and inflammatory myofibroblastic tumor (14–16), \( FN1-IGF1R \) in ALK-negative inflammatory myofibroblastic tumor (17), and \( FN1-ROS1 \) in infantile inflammatory myofibroblastic tumors (18).

Soft tissue chondromas in general are characterized by nodular/lobular growth of well-differentiated chondrocytes. However, the chondroblastic-like variant of soft tissue chondroma as described by Cates et al. (2001) also shows cellular foci of epithelioid chondrocytes of varying size admixed with osteoclast-like giant cells within a variable amount of chondroid matrix that is frequently accompanied by lace-like calcification (19). While most cases of soft tissue chondroma have been documented to occur in the extremities, lesions involving the parotid region and skull base has been reported (20). The cases in our series, particularly the ones with
*FN1-FGFR1, FN1-FGFR2* and *FN1-MERTK* fusions, show significant morphologic overlap with previous morphologic descriptions of the chondroblastoma-like variant of soft tissue chondroma; however, we also describe TGCT-like features as well as CPPD crystal deposition, expanding the morphologic spectrum of this group of entities. We also report a larger proportion affecting the temporomandibular joint (TMJ) region. We therefore believe that this group of neoplasms may not be best classified as simply a variant of soft tissue chondroma and have chosen to apply the term “calcified chondroid mesenchymal neoplasm” for the purposes of this study.

A few of the cases in our series warrant special consideration (see a summary of differential diagnosis in table 2). One tumor involving the TMJ and harboring *FN1-FGFR2* (case 5) showed extensive deposition of calcium pyrophosphate dehydrate (CPPD) crystals. Tophaceous pseudogout is a mass-forming (tumoral) deposition of CPPD crystals that has been described in a number of locations near joints including the TMJ and some show erosion into the skull base (7,21,22). Cellular infiltrates resembling foreign body type giant cell reaction are typically present, and cartilage/chondroid tissue (supposedly metaplastic) may also be seen in a significant subset of examples (7,22). While only one fusion-positive case in our series contained CPPD deposition, this observation calls into question whether tumoral (massive) tophaceous pseudogout, or at least a subset of cases, actually represent neoplasms harboring recurrent gene fusions.

For the one tumor in our series harboring an *FN1-FGFR1* fusion gene (Figure 5B, case 7), we considered the possibility of phosphaturic mesenchymal tumor (PMT). PMTs can take on a wide range of histologic appearances, but in general are characterized having a highly vascular stroma (some with hemangiopericytoma-like pattern) with bland spindled to stellate neoplastic
cells and amorphous basophilic chondro-osseous matrix with grungy calcification (4,23,24). A significant subset of PMT was also shown to harbor FNI-FGFR1 fusions and are frequently associated with hypophosphatemia and tumor-induced osteomalacia secondary to paraneoplastic secretion of the fibroblast growth factor 23 (FGF23) (3,12). Examples of PMT without apparent tumor-induced osteomalacia, however, have also been described (24) as well as fusion-negative cases that frequently overexpress α-klotho, a transmembrane enzyme that acts as an FGF23 activator (25). α-Klotho interacts directly with FGFR1 and forms a high-affinity binding site at Ig3 domain for FGF23 (26). None of the cases in our series, including the one with FNI-FGFR1, exhibited the highly vascular stroma or spindle cell proliferation typical of PMT and none of these patients had any known osteomalacia. Given the absence of phosphaturia and definitive histologic features of PMT, this case is best classified as a chondroblastoma-like soft tissue chondroma. Furthermore, unlike most of FNI-FGFR1 fusions characterized by sequencing in PMT which retained mostly all 3 or 2 of Ig domains of FGFR1 (3,12,27,28), FNI-FGFR1 fusion in case 7 did not contain any Ig domains of FGFR1 (Figure 5B). Without the Ig3 domain, the FNI-FGFR1 fusion protein could not interact with FGF23. The recent description of FNI-FGFR1 fusions in three cases of soft tissue chondroma were indirectly demonstrated using break-apart FISH probes for FNI and FGFR1 without the knowledge of protein domains retained (2). It would be informative to assess whether these three cases retain any Ig domain. The lack of significant levels of FGF23 in these three cases of soft tissue chondromas suggest a potential lack of Ig domains in their fusions. In all, our study has demonstrated the effectiveness of RNA-seq as a tool for identifying functional domains retained in gene fusions and in turn facilitating correlation of molecular findings with clinicopathological features and tumor classification.
We detected an \textit{FGFR1-PLAG1} in one case involving the TMJ. \textit{FGFR1-PLAG1} fusions have been previously detected in pleomorphic adenoma (PA) of salivary gland origin and, in such cases, the 5’-portion of \textit{FGFR1}, excluding the tyrosine kinase domain, is fused to the entire \textit{PLAG1} coding sequence (29,30). This fusion gene arrangement is the same as that found in case 6 of our series. While PA is principally defined histologically by the proliferation of ductal and myoepithelial cells within hyalinized to myxoid stroma, cartilaginous components may also be seen and can be quite extensive (31). Our case was entirely composed of lobular cartilaginous tissue with variable, often grungy, calcification without any identifiable ductal or myoepithelial population and therefore histologically appeared essentially indistinguishable from the other chondroblastoma-like soft tissue chondromas in our series. In such an archived case, excluding the possibility of a PA with extensive cartilaginous components in which ductal/myoepithelial components were either not present or not sampled is problematic; however, we found no morphologic features to classify it as PA. We must also consider the possibility that \textit{FGFR1-PLAG1} may represent an alternate fusion gene found in non-PA soft tissue cartilaginous neoplasms.

Chondroid tenosynovial giant cell tumor (TGCT) is a rare tumor with a predilection for the TMJ region and skull base that often demonstrates locally aggressive growth including bone destruction (5,6,32–34). Histologically, chondroid TGCT shows features of conventional TGCT, such as sheet-like proliferation of large epithelioid to histiocytoid mononuclear cells, some with hemosiderin deposition often in a ring like deposition around the cytoplasm, and multinucleated giant cells; however, geographic or nodular areas of metaplastic chondroid matrix are also present and frequently associated with grungy, lace-like calcifications. While the majority of conventional TGCTs have been shown to harbor \textit{CSF1} fusions (35), this disease-specific genetic
event has not been demonstrated in chondroid TCGT of the TMJ. The case with *FN1-TEK*
fusion in our study shows prominent morphologic features resembling TGCT with focal areas of
chondroid matrix and calcifications as seen in the other cases in the series. This finding raises the
possibility that lesions previously classified as chondroid TGCT may actually fall into this group
of calcified chondroid mesenchymal neoplasms with *FN1* gene fusions. For comparison, we
tested another case from our archives previously classified as TGCT with chondroid metaplasia
occurring in the TMJ (Figure 4 C-D), and that tumor tested negative for gene fusions, including
*FN1, FGFR1, FGFR2* and *CSF1*, using our targeted gene panel. It remains to be determined
whether any other tumors previously described as chondroid TGCT harbor recurrent gene
fusions including an *FN1*-tyrosine kinase receptor fusion.

Additional differential diagnostic considerations include chondroblastoma and synovial
chondromatosis. Chondroblastoma most often occurs in the epiphyses of long bones but may
also affect the craniofacial skeleton. Histologically, it is characterized by sheets of uniform
round to polygonal mononuclear cells with distinct cell borders and grooved nuclei with
scattered islands of cartilaginous differentiation often showing lacy (“chicken-wire”)
calcification (36). While some of our cases show a lacy calcification pattern within the
cartilaginous elements, our tumors generally lack the sheet-like cellularity and characteristic
cytomorphology of chondroblastoma. Lacy (chondroblastoma-like) calcifications have also
been previously described in chondroblastoma-like soft tissue chondroma (19,20,37). In
addition, *H3F3B*K36M mutation has been detected in greater than 90% of chondroblastomas
and immunohistochemical staining using a mutation specific antibody has been shown to be
highly sensitive and specific (38,39). Immunohistochemical staining for the K36M mutant was
negative in one case with *FN1-FGFR2* fusion (Case 2). Synovial chondromatosis is
characterized by a strikingly nodular proliferation of fairly uniform, mature, hyaline, cartilaginous tissue, often with distinct clustering of chondrocytes, which involves the joint synovium, tendon sheath, or bursa. A subset of cases harbors *FN1-ACVR2A* fusion and this finding has been described as a distinguishing feature of synovial chondromatosis from soft tissue chondroma (2). While the tumors in our series do show lobulated growth of cartilaginous tissue, they lack the distinct clustering of chondrocytes and are negative for the *FN1-ACVR2* fusion gene. Overall, our findings indicate that the tumors in our series represent distinct entities from both chondroblastoma and synovial chondromatosis.

In summary, our study presents 9 examples of “calcified chondroid mesenchymal neoplasm,” 8 of which harbor FN1-receptor tyrosine kinase fusions showing a predilection for the TMJ region as well as the extremities. The *FN1* fusions with receptor tyrosine kinase genes include *FN1-FGFR2, FN1-FGFR1* (without Ig3 domain), as well as the novel fusions *FN1-MERTK* and *FN1-TEK*. Unlike the *FN1-FGFR1* fusions found in PMT, the *FN1-FGFR1* fusion detected in our series did not retain the Ig3 domain of FGF23 binding site. While most cases in our series (particularly the ones with *FN1-FGFR1, FN1-FGFR2* and *FN1-MERTK1* fusions) show morphologic overlap with chondroblastoma-like soft tissue chondroma, we also report the novel findings of extensive CPPD crystal deposition in one case and extensive morphologic features resembling TGCT, expanding the morphologic spectrum of tumors with *FN1*-receptor tyrosine kinase fusions beyond those previously described for soft tissue chondroma. Our findings also raise the question of whether some lesions previously classified as tophaceous pseudogout and chondroid TGCT may actually represent neoplasms harboring recurrent *FN1* gene fusions. The presence of *FGFR1-PLAG1* in one of our cases suggests that pleomorphic adenoma of salivary gland origin should be considered in the differential diagnosis of cartilage.
lesions affecting the craniofacial region. While most of these tumors are amenable to surgical excision, the structure of these fusion genes indicates that therapeutic targeting of the receptor tyrosine kinases may be a promising alternative treatment avenue if needed.

**ACKNOWLEDGMENTS:** This project is supported by intra-departmental funding.

**DISCLOSURE/CONFLICT OF INTEREST:** The authors have no conflict of interest to declare.

**FIGURE LEGEND:**

Figure 1. Major histologic features of soft tissue cartilage neoplasms in this study. (A-B) Characteristic lobular architecture in cases 2 (A) and 4 (B). (C-D) Grungy to lacey (chondroblastoma-like) calcifications in cases 2 (C) and 4 (D).

Figure 2. Case 5 with CPPD crystal deposition. (A-B) Case 5 with extensive basophilic grungy calcification at low power (A) and epithelioid to differentiated chondrocytes within crystalline deposits at high power (B). (C) Refractile rhomboid crystals when viewed using polarized light consistent with CPPD.

Figure 3. Cytologic features of the soft tissue cartilage neoplasms in this study. (A-C) Cells within chondroid matrix are polygonal to stellate with abundant eosinophilic cytoplasm and eccentrically placed nuclei with small nucleoli, while septae separating lobules contain spindled
fibroblastic cells. Osteoclast giant cells are also a frequent finding. (A) Case 2. (B) Case 3. (C) Case 8.

Figure 4. Soft tissue cartilage neoplasm in this study with features resembling tenosynovial giant cell tumor (TGCT). (A-B) Case 9 that predominantly shows the histologic features of epithelioid cells with eccentric nuclei admixed with osteoclast-like giant cells, resembling some features of a TGCT (A) as well as focal area of epithelioid to stellate cells in chondroid matrix with calcification (B). (C-D) Case of a TGCT occurring in the TMJ for comparison with case 9 showing mononuclear epithelioid/histiocytoid cells with eccentric nuclei and ring-like distribution of cytoplasmic hemosiderin as well as multinucleated giant cells (C). Focal area of chondroid metaplasia is present (D).

Figure 5. Schematic of chimeric transcripts and proteins resulting from gene fusions. (A). RNA transcripts with exon structures and related protein domains in the genes involved in the fusions. (B). Chimeric transcripts and proteins detected in the cohort of soft tissue chondroma of this study and related tumors in the literature, showing the retained exons and functional domains of the fusion genes of FN1, FGFR2, FGFR1, MERTK, and PLAG1. Case 102 is the only case with FN1-FGFR2 characterized by RNA-seq previously (2). *PMTs = Phosphaturic Mesenchymal Tumors with FN1-FGFR1 fusions and range of breakpoints reported in the literature (3,12,25,27,28). *PAs = pleomorphic adenoma of salivary gland origin with FGFR1-PLAG1 fusions and range of breakpoints reported in the literature (40). Untranslated regions (5′ UTR and 3′ UTR) are shown as narrow bars. Exons are shown as boxes with numbers. Protein domains are represented by shapes with keys shown in the box: SP = Signal Peptide, FN type 1 domain, FN
type 2 domain, FN type 3 domain, EGF=EGF-like domain, Ig=Immunoglobulin-Like loop domain, TM = Transmembrane domain, and TK = Tyrosine Kinase, C2H2 Zn =C2H2 Zn finger, and NLS=Nuclear localization signal.
REFERENCES


24. Sent-Doux KN, Mackinnon C, Lee J-C, Folpe AL, Habeeb O. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the “nonphosphaturic” variant, with


Figure 1
Figure 2
Figure 4
A. Genes in the fusions

- **FN1**
- **FGFR2**
- **MERTK**
- **FGFR1**
- **TEK**
- **PLAG1**

**Protein domains**
- SP
- FN I
- FN II
- FN III
- EGF
- Ig
- TM
- TK
- C2H2 Zn
- NLS

**Genes/exons**
- **FN1**
- **FGFR2**
- **MERTK**
- **FGFR1**
- **TEK**
- **PLAG1**

**B. Fusion genes**

- **FN1 – FGFR2 (E42~11::E5~7)** in cases 1-5 and case 102 (Amary 2019)
- **FN1 – MERTK (E24::E2)** in case 8
- **FN1 – TEK (E27::E17)** in case 9
- **FN1 – FGFR1 (E25::E9)** in case 7
- **FN1 – FGFR1 (E28~16::E3~9)** in PMTs*
- **FN1 – FGFR1 (E1~2::E2~3)** in case 6 and in PAs*
<table>
<thead>
<tr>
<th>Number</th>
<th>Age</th>
<th>Sex</th>
<th>Location</th>
<th>Size (cm)</th>
<th>Recurrence</th>
<th>Metastasis</th>
<th>Fusion (5' exon::exon 3')</th>
<th>Genomic coordinates [hg19]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>70</td>
<td>M</td>
<td>TMJ</td>
<td>4.0 cm</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → FGFR2 (E15::E7)</td>
<td>chr2:216274286,chr10:123279683</td>
</tr>
<tr>
<td>2</td>
<td>66</td>
<td>F</td>
<td>TMJ</td>
<td>3.9 cm</td>
<td>No (1 year)</td>
<td>No</td>
<td>FN1 → FGFR2 (E42/ E38::E5)</td>
<td>chr2:216232586,chr2:216238045,chr10:123310973</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>F</td>
<td>Foot</td>
<td>3.8 cm</td>
<td>No (1 year)</td>
<td>No</td>
<td>FN1 → FGFR2 (E31::E5)</td>
<td>chr2:216246935,chr10:123310973</td>
</tr>
<tr>
<td>4</td>
<td>52</td>
<td>F</td>
<td>Hand</td>
<td>0.5 cm</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → FGFR2 (E11::E5)</td>
<td>chr2:216285396,chr10:123310973</td>
</tr>
<tr>
<td>5</td>
<td>72</td>
<td>F</td>
<td>TMJ</td>
<td>Unknown</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → FGFR2 (E17::E5)</td>
<td>chr2:216272831,chr10:123310973</td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>F</td>
<td>TMJ</td>
<td>Unknown</td>
<td>NA</td>
<td>NA</td>
<td>FGFR1 → PLAG1 (E1::E3)</td>
<td>chr8:38325499,chr8:57083748</td>
</tr>
<tr>
<td>7</td>
<td>36</td>
<td>M</td>
<td>5th finger-palm</td>
<td>Unknown</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → FGFR1 (E25::E9)</td>
<td>chr2:216256355,chr8:38277253</td>
</tr>
<tr>
<td>8</td>
<td>51</td>
<td>M</td>
<td>Thumb</td>
<td>Unknown</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → MERTK (E24::E2)</td>
<td>chr2:216259251,chr2:112686697</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>M</td>
<td>Temporal/external auditory canal</td>
<td>Unknown</td>
<td>NA</td>
<td>NA</td>
<td>FN1 → TEK (E27::E13)</td>
<td>chr2:216251412,chr9:27202818</td>
</tr>
</tbody>
</table>

Note:  
- Exon numbers were based on the transcript numbers of genes used for FN1 (NM_002026.2), FGFR2 (NM_000141.4), MERTK (NM_006343.2), FGFR1 (NM_015850.3), TEK (NM_000459), and PLAG1 (NM_002655.2);  
- TMJ, temporomandibular joint;  
- NA, not available;  
- Only breakpoints reported for FN1-FGFR2 fusion (2);  
- Two alternatively spliced variants detected in case 2;  
- Breakpoints differ from what was reported for the FN1-FGFR1 fusions detected in phosphaturic mesenchymal tumors (3, 12, 27, 28)
Table 2. Summary of differential diagnosis.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Soft tissue chondroma</th>
<th>Chondroblastoma</th>
<th>Phosphaturic Mesenchymal Tumor</th>
<th>Chondroid TGCT</th>
<th>CPPD Tophus</th>
<th>Synovial Chondromatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median/Average Age</td>
<td>40s to 50s</td>
<td>20s</td>
<td>50s</td>
<td>40s to 60s</td>
<td>60s</td>
<td>40s</td>
</tr>
<tr>
<td>Site</td>
<td>Extremities and TMJ</td>
<td>Long, flat and short bones</td>
<td>Extremities (95%), head and neck (5%)</td>
<td>TMJ (most common), other sites: ear, groin</td>
<td>TMJ, hip, vertebrae, toe</td>
<td>Knee (most common) extremities, hip</td>
</tr>
<tr>
<td>Margins</td>
<td>Well-circumscribed</td>
<td>Well-circumscribed</td>
<td>Well-circumscribed or infiltrative</td>
<td>Well-circumscribed</td>
<td>Well-circumscribed</td>
<td>Well-circumscribed</td>
</tr>
<tr>
<td>Growth Pattern/ Appearance</td>
<td>Lobular/nodular</td>
<td>Lobular or sheet-like</td>
<td>Variegated</td>
<td>Lobular/nodular</td>
<td>Lobular</td>
<td>Lobular/nodular</td>
</tr>
<tr>
<td>Matrix</td>
<td>Chondroid, the chondroblastoma-like variant with lace-like pericellular calcifications, some with ossification or CPPD deposition</td>
<td>Chondroid, some with calcifications of various patterns (including classic lace-like)</td>
<td>Grungy calcifications, chondroid/osseous matrix, rich capillary network, woven bone production</td>
<td>Chondromyxoid, hyaline cartilage metaplasia or chondro-osseous with frequently lace-like, pericellular grungy calcifications</td>
<td>Grungy calcifications, occasional chondroid metaplasia</td>
<td>Mature cartilage with frequent enchondroosification and/or calcifications</td>
</tr>
<tr>
<td>Cytomorphology</td>
<td>Mature chondrocytes, chondroblastoma-like variant with polygonal, stellate to spindled chondrocytes</td>
<td>Uniform round to polygonal monocellular cells with well-defined border and nuclear grooves</td>
<td>Bland spindle cells (except for malignant form)</td>
<td>Proliferation of large epithelioid and small histiocytoid monocellular cells admixed with histiocytes (some hemosiderin-laden) and lymphocytes</td>
<td>Needle to rhomboid-shaped crystals, associated with histiocytes and occasionally osteoclast-like giant cells</td>
<td>Mature round to polygonal chondrocytes</td>
</tr>
<tr>
<td>Osteoclast-like giant cells</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Other Features</td>
<td>Secondary aneurysmal bone cyst-like changes, woven bone matrix</td>
<td>Secondary, FNI-FGFR2, FNI-FGFR1 (without Ig domain), FNI-MERTK</td>
<td>H3F3B mutation (K36M)</td>
<td>FNI-FGFR1 with FGF23 expression, FNI–FGF1</td>
<td>CSF1 fusion in a subset of conventional TGCTs</td>
<td>FN1–ACVR2A</td>
</tr>
<tr>
<td>Molecular Findings</td>
<td>FN1–FGFR2, FN1–FGFR1 (without Ig domain), FNI–MERTK</td>
<td>H3F3B mutation (K36M)</td>
<td>FNI–FGFR1 with FGF23 expression, FNI–FGF1</td>
<td>CSF1 fusion in a subset of conventional TGCTs</td>
<td>FN1–ACVR2A</td>
<td></td>
</tr>
<tr>
<td>Recurrence Potential</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Metastasis Potential</td>
<td>N</td>
<td>Y (rare, &lt;5%)</td>
<td>Y (Malignant form)</td>
<td>N</td>
<td>N</td>
<td>Y (secondary chondrosarcoma)</td>
</tr>
<tr>
<td>Reference</td>
<td>(2,19,20)</td>
<td>(8,36,38-39)</td>
<td>(4,12,23,24,27)</td>
<td>(5,9,32-34)</td>
<td>(7,21,22)</td>
<td>(2)</td>
</tr>
</tbody>
</table>